A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer

NCT05042375 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

450

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: camrelizumab + famitinib
DRUG: pembrolizumab
DRUG: camrelizumab

Sponsor

Jiangsu HengRui Medicine Co., Ltd.